Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Clinical Trials: Overview01:11

Clinical Trials: Overview

4.5K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
4.5K
Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

953
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
953
Clinical Trials01:16

Clinical Trials

10.1K
Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
10.1K
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

772
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
772
Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

1.7K
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
1.7K
Preclinical Development: Overview01:28

Preclinical Development: Overview

5.7K
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
5.7K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Genetic or pharmacological disruption of the MSH3 Y245/K246 IDL binding pocket slows CAG repeat expansion.

NAR molecular medicine·2026
Same author

Targeting toxic HTT1a could be the key to treating Huntington disease.

Nature reviews. Neurology·2026
Same author

Longitudinal assessment of chorea in Huntington's disease using digital passive monitoring.

NPJ digital medicine·2026
Same author

Shape matters: Predicting Huntington's disease using progression modelling.

Computer methods and programs in biomedicine·2026
Same author

Discovery of disrupted sustained attention and altered functional connectivity in far-from-onset Huntington's disease gene-expanded young adults.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same author

Oral splicing modulator branaplam in Huntington's disease: a phase 2 randomized controlled trial.

Nature medicine·2026
Same journal

Phase-targeted auditory stimulation enhances slow-wave activity during sleep in Huntington's disease: A pilot crossover study.

Journal of Huntington's disease·2026
Same journal

Differential sensitivity of the MMSE and MoCA for staging and longitudinal cognitive change in Huntington's disease.

Journal of Huntington's disease·2026
Same journal

Clinical implications of loss of interruption variants for diagnosis, genetic counselling, and clinical trials in Huntington's disease.

Journal of Huntington's disease·2026
Same journal

Preface to special issue on neurodevelopment in Huntington's disease.

Journal of Huntington's disease·2026
Same journal

The sparse evidence-base for self-injurious behavior in Huntington's disease: A call to action.

Journal of Huntington's disease·2026
Same journal

The holistic burden of Huntington's disease: A qualitative study of multigenerational impact on individuals and family caregivers across Europe.

Journal of Huntington's disease·2026
See all related articles

Related Experiment Video

Updated: Jan 10, 2026

Efficient and Scalable Production of Full-length Human Huntingtin Variants in Mammalian Cells using a Transient Expression System
10:52

Efficient and Scalable Production of Full-length Human Huntingtin Variants in Mammalian Cells using a Transient Expression System

Published on: December 10, 2021

3.0K

Huntington's disease clinical trials update: October 2025.

Mena Farag1, Sarah J Tabrizi1, Edward J Wild1

  • 1Huntington's Disease Centre, UCL Queen Square Institute of Neurology, London, UK.

Journal of Huntington'S Disease
|November 26, 2025
PubMed
Summary
This summary is machine-generated.

This update covers new Huntington's disease clinical trials, including SKY-0515 and SPK-10001. Positive 36-month data for AMT-130 and updates on tominersen, PTC-518, and pridopidine are also discussed.

Keywords:
Huntington's diseaseclinical trials

More Related Videos

Fractionation for Resolution of Soluble and Insoluble Huntingtin Species
07:08

Fractionation for Resolution of Soluble and Insoluble Huntingtin Species

Published on: February 27, 2018

10.0K
Single Synapse Indicators of Glutamate Release and Uptake in Acute Brain Slices from Normal and Huntington Mice
08:27

Single Synapse Indicators of Glutamate Release and Uptake in Acute Brain Slices from Normal and Huntington Mice

Published on: March 11, 2020

6.5K

Related Experiment Videos

Last Updated: Jan 10, 2026

Efficient and Scalable Production of Full-length Human Huntingtin Variants in Mammalian Cells using a Transient Expression System
10:52

Efficient and Scalable Production of Full-length Human Huntingtin Variants in Mammalian Cells using a Transient Expression System

Published on: December 10, 2021

3.0K
Fractionation for Resolution of Soluble and Insoluble Huntingtin Species
07:08

Fractionation for Resolution of Soluble and Insoluble Huntingtin Species

Published on: February 27, 2018

10.0K
Single Synapse Indicators of Glutamate Release and Uptake in Acute Brain Slices from Normal and Huntington Mice
08:27

Single Synapse Indicators of Glutamate Release and Uptake in Acute Brain Slices from Normal and Huntington Mice

Published on: March 11, 2020

6.5K

Area of Science:

  • Neurology
  • Genetics
  • Clinical Trials

Background:

  • Huntington's disease (HD) is a progressive neurodegenerative disorder.
  • Effective treatments and clinical trial advancements are crucial for managing HD.

Purpose of the Study:

  • To provide a comprehensive update on ongoing and recently launched clinical trials for Huntington's disease.
  • To report key findings and developments from various HD therapeutic programs.

Main Methods:

  • Review of recently launched Phase II/III and Phase I/II clinical trials.
  • Analysis of topline data from ongoing studies, including long-term follow-up.
  • Discussion of regulatory updates and program developments.

Main Results:

  • Positive topline data reported for AMT-130 (uniQure) after 36 months.
  • Updates on SKY-0515 (Skyhawk Therapeutics) and SPK-10001 (Spark Therapeutics) trials.
  • Progress noted for tominersen (Roche), PTC-518 (PTC Therapeutics), and collaborative programs.

Conclusions:

  • The Huntington's disease therapeutic landscape is dynamic with multiple promising clinical trials underway.
  • Continued monitoring of trial progress and regulatory developments is essential for the HD community.